Biotechnology, Clinical trial, Pharmacology, Pharmaceutical industry, Carcinogen, Novo Nordisk
Covid-19 roundup: EU and AstraZeneca trade blows over slowdowns; Unusual unions pop up to test antibodies, vaccines
Covid-19 roundup: In unusual unions, Eli Lilly tests antibody combo with GlaxoSmithKline while Sanofi pledges to make 100M doses of Pfizer's vaccine
https://t.co/7tGSvrZMYz
OpenAfter coming under fire for manufacturing delays last week, AstraZeneca’s feud with the European Union has spilled into the open. The bloc accused the pharma giant on Wednesday of pulling out of a meeting to discuss cuts to its vaccine supplies, the AP reported. ...
Covid-19 roundup: In unusual unions, Eli Lilly tests antibody combo with GlaxoSmithKline while Sanofi pledges to make 100M doses of Pfizer's vaccine
https://t.co/7tGSvrZMYz
OpenCovid-19 roundup: EU and AstraZeneca trade blows over slowdowns; Unusual unions pop up to test antibodies, vaccines
After coming under fire for manufacturing delays last week, AstraZeneca’s feud with the European Union has spilled into the open. The bloc accused the pharma giant on Wednesday of pulling ...
We are sorry, we could not find the related article
If you are curious about Biotech Essentials, the Influencers Review and Career and Jobs
Please click on:
Or signup to our newsletters
AstraZeneca CEO Pascal Soriot severs an unusual board connection, steering clear of conflicts while retaining important alliances
CSL Behring chief Paul Perreault scored an unusual coup last summer when he added AstraZeneca CEO Pascal Soriot to the board, via Zoom. It’s rare, to say the least, to see a Big Pharma CEO ...
A Year to Remember: The Biggest European Biotech News in 2020
The Covid-19 pandemic caused huge disruption for European biotech in 2020, but the industry pulled through. Let’s look back at some of the top moments in the last 12 months. After the many ...
They Pledged to Donate Rights to Their COVID Vaccine, Then Sold Them to Pharma
Advocates of cheap and widely available vaccines thought the pandemic might change business as usual. They were wrong.
Bio Roundup: Cerevel’s Shell, Thrive’s Rise, Drug Price Drama & More
The biotech IPO market is buzzing but Cerevel Therapeutics is showing that there’s more than one path to the public markets. This week the neuroscience
AstraZeneca
[3] It has Research and development concentrated in three strategic centres; Cambridge, Gothenburg, Sweden and Gaithersburg, U.S.[4] AstraZeneca has a portfolio of products for major ...
Alzheimer’s Disease: Global Drug Forecast and Market Analysis to 2028
Last Wednesday saw Gilead Sciences hand back most rights to rheumatoid arthritis drug Jyseleca (filgotinib) to Belgian partner Galapagos. Finding the next Prevail Jacob Plieth also ...